

[View this email in your browser](#)



VALIDATING DIAGNOSTICS TO
COMBAT ANTIMICROBIAL RESISTANCE
BY OPTIMISING ANTIBIOTIC USE

 WWW.VALUE-DX.EU

VALUE-Dx Leaflet

VALUE-Dx has published a leaflet explaining our research into diagnostic strategies to achieve a more **personalised, evidence-based antibiotic prescription and use in the community care settings to combat antimicrobial resistance (AMR)**. [Download the leaflet](#) to learn more about the our project and the studies we are conducting.



[Download the leaflet](#)

RECOVER builds on the work of VALUE-Dx to combat COVID-19 pandemic

On 11 March 2020, the University of Antwerp has launched [Rapid European COVID-19 Emergency Research response \(RECOVER\)](#), in collaboration with 9 international partners. RECOVER's Primary Care Studies are leveraging the work done by the VALUE-Dx, such as the Point Prevalence Audit Survey (PPAS) to contribute to informing the planning, policy, communication, and clinical management of the COVID-19 pandemic. [Read more](#)



Review and analysis of diagnostic test accuracy for CA-ARTI

VALUE-Dx is working on identifying the optimal tests that can diagnose reliably all patients with specific Community-Acquired Acute Respiratory Tract Infections (CA-ARTIs). Our researchers conducted a systematic review and meta-analysis of point-of-care diagnostic test accuracy (DTA) for CA-ARTI including Rapid Antigen Detection Technique (RADTs), Nucleic acids amplification tests, imaging techniques, signs and symptoms, and host biomarkers. [Read more](#)



Enhancing the quality of antibiotic prescribing for CA-ARTI in Emergency Rooms through ADEQUATE trial

ADEQUATE (Advanced Diagnostics for Enhanced QQuality of Antibiotic prescription in respiratory Tract infections in Emergency rooms) is a randomized controlled trial of Rapid Syndromic Diagnostic testing versus current local Standard Of Care for enhancing the quality of antibiotic prescribing for CA-ARTI in Emergency Rooms in Europe. ADEQUATE aims to assess the impact of rapid syndromic diagnostic testing in patients with Acute Respiratory Tract Infection (ARTI) at the emergency department, on hospital admission rates and antimicrobial prescriptions (days of treatment) and the non-inferiority in terms of clinical outcome. [Read more](#)




CA-ARTI diagnostics through PRUDENCE trial

PRUDENCE (Platform Randomised controlled trial of point of care Diagnostics for Enhancing the quality of aNtibiotic prescribing for Community acquired acute respiratory tract infection (CA-ARTI) in ambulatory care in Europe) is a multi-country, prospective, individually randomised, platform clinical trial in community care with a nested process evaluation. The aim of PRUDENCE is to determine if having a CA-ARTI diagnostic (CA-ARTI-Dx) test result available when a clinician is considering, or plans to prescribe an antimicrobial, leads to more appropriate prescribing decisions, without causing harm to patients. The trial is a diagnostic strategy intervention study to evaluate the use of clinical algorithms that include a CA-ARTI-Dx, compared to usual clinical care without CA-ARTI-Dx. [Read more](#)



VALUE-Dx work on investigating value of diagnostics

Why would patients, doctors, health insurers and governments pay for tests that are six times more expensive than the accompanying treatment? Finding answers to above questions and solutions for improvement of underlying mechanisms requires an interdisciplinary approach: our research therefore integrates a variation of tasks and viewpoints, distributed over various organizations. [Read more](#)




VALUE-Dx gets ready for clinical trials

VALUE-Dx Laboratory Analyses and Biobanking work encompasses microbiology work performed on clinical samples obtained from VALUE-Dx clinical trials, as well as biobanking. As the clinical trials have not started yet, no actionable results have been obtained so far. However, the Laboratory Analyses and Biobanking team has been working on the optimization of the methods to be used once the samples are received. Specifically, work has been performed on the aetiology elucidation from clinical samples based on next generation sequencing (NGS) techniques. [Read more](#)



Extended PPAS during COVID-19 pandemic

presentation and management of patients with acute respiratory tract infection during the COVID-19 pandemic. This registration additionally focuses on the organisation of primary care during the pandemic and what additional testing and (preventive) measures were taken and advised to patients. [Read more](#)



UPCOMING EVENTS

- [TBD: VALUE-Dx General Assembly, Bologna, Italy](#)



Innovative
Initiative

EFPIA



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is:

value_dx@uantwerpen.be

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Organisation · Universiteitsplein · Wilrijk 2160 · Belgium

